Lyfgenia® (lovotibeglogene autotemcel)
for Sickle Cell DIsease

Lyfgenia (lovotibeglogene autotemcel) is a gene therapy given as a one-time intravenous suspension to treat adults and children aged 12 and older with sickle cell disease (SCD) and a history of vaso-occlusive crises (VOCs). Lyfgenia uses a viral vector to deliver genetic modifications to the patient’s blood stem cells, allowing the production of anti-sickling hemoglobin. This reduces or eliminates VOCs by producing functional beta-globin, without the need for a donor.

Heart
Medication Guide Icon Medication Guide
Patient Website Icon Patient Website
Efficacy Data Icon Efficacy Data
New Articles Icon New Articles
Savings and Support Icon Savings and Support
Company MD Payments Icon Company MD Payments
Clinical Trials Icon Clinical Trials
Adverse Event Report Icon Adverse Event Report
Other top medicines used to treat Sickle Cell Disease